A new study links the use of the common chemotherapy drug cisplatin with later hearing loss The study of testicular cancer survivors found the extent of hearing loss rose along with the dose of cisplatin taken Patients may want to discuss what options they have for chemotherapy, given the findings MONDAY, July 1, 2024 (HealthDay news) -- A 14-year study of testicular cancer survivors suggests that a chemotherapy drug could greatly raise patients' long-term odds for hearing loss. The drug in question, , has been a mainstay of cancer chemotherapy for decades. It's often used to fight a range of cancers, including including bladder, lung, neck and testicular tumors.
Knowing that cisplatin might impact people's hearing could help guide treatment, said study co-author . He's chair of the department of medical engineering at the University of South Florida (USF). “This research gives oncologists the information they need to explore alternative treatment plans that could reduce the long-term side effects," he said in a USF news release.
Such changes might include "altering the dosages and timing of the cisplatin in the treatment, when that could be an appropriate option,” Frisina explained. The findings were published recently in the journal . The study was led by , an associate professor of otolaryngology head & neck surgery at USF.
Over an average of 14 years, her team tracked the health of 100 men who'd been treated for and survived testicular cancers. The researchers found t.
